ABT ADA Weekend Highlighted by Ketone Monitoring and FreeDM2 Sub-analysis

Research evidence excerpt

ABT ADA Weekend Highlighted by Ketone Monitoring and FreeDM2 Sub-analysis

Medical Supplies & Devices

Abbott Laboratories

TD SECURITIES (USA) LLC COMPANY UPDATE

June 9, 2026

Price: $90.50 (06/8/2026) ABT ADA Weekend Highlighted by Ketone

Price Target: $115.00 Monitoring and FreeDM2 Sub-analysis

BUY (1)

ESG SCORE: 58/100

Joshua Jennings, M.D. THE TD COWEN INSIGHT

646 562 1333

Coming out of the meeting, ABT's efforts in Ketone monitoring and favorable early Instinct

joshua.jennings@tdsecurities.com

receptivity bolster our confidence that the company is best positioned to take share in the T1

Colin Clark and AID markets. While a CGKS consensus has not yet been reached, ABT is already laying

646 562 1441 the groundwork to build this market, evidenced by updated ADA guidelines, which include an

colin.clark@tdsecurities.com

elevated ketones/DKA decision tree.

John Rusch, CFA

646 562 1324 ABT ADA Weekend Overview

john.rusch@tdsecurities.com

ABT's ADA 2026 presentation highlighted an increasingly ambitious vision for the Libre

Key Data ecosystem. Libre Assist expands the platform into AI-driven behavioral coaching, addressing

Symbol NYSE: ABT

one of the most significant challenges in Type 2 diabetes management - food decision-making.

Beta: 0.62 Meanwhile, Libre Duo establishes ABT as the first major CGM manufacturer pursuing broad

52-Week Range: $138.08-$82.56 commercialization of continuous ketone monitoring, potentially opening an entirely new

Market Cap: $157.6B category centered on DKA prevention. These innovations suggest ABT's future growth strategy

Net Debt (MM): $26,752.0 extends well beyond sensor penetration. The company is increasingly positioning Libre as

Cash/Share: $4.22 a comprehensive metabolic intelligence platform that combines continuous monitoring, AI-

Dil.